摘要:
The present invention relates to novel quinoxaline compounds of Formula I: as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the quinoxaline compounds and the use of the quinoxaline compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.
摘要:
A method of decomposing stubble, which is crop residue left on the ground, and a composition for treating the stubble are disclosed. The method comprises treating the stubble with the composition comprising a) polysaccharide-degrading enzyme; b) wetting agent; and, optionally, c) water and allowing the treated stubble to remain on the ground and decompose.
摘要:
The invention relates to process for the treatment of a hydrophobic surface by a liquid film comprising an aqueous phase comprising the coating of said surface by the liquid whose aqueous phase comprises an effective amount of surface properties modifying agent and an active agent.
摘要:
A surface modified substrate includes a substrate having a surface and a layer of nanoscale inorganic oxide particles disposed on at least a portion of the surface.
摘要:
The present invention relates to extended release pharmaceutical compositions of Levetiracetam and processes for preparing the same. The extended release tablet of Levetiracetam is with a core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patient's blood plasma. The composition also exhibits no food effect.
摘要:
An extended release pharmaceutical composition comprising levetiracetam. A coated extended release pharmaceutical composition comprising levetiracetam wherein the core is coated with a rate controlling composition.
摘要:
For improving the accuracy of a speech recognition system, for the specific task of speech-to-text (dictation style speech) translation, a constrained dictation methodology using speak-and-spell mode is disclosed. The invention is perfectly suited for modern day “text-messaging” applications wherein the number of words being dictated is very small (limited by the 140-160 characters message length constraint). Additionally, the invention adds a control on the way users interact with machines, thereby making the speech recognition task easier and improving system accuracy.
摘要:
The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).
摘要:
A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.
摘要:
A compound having the general structure shown in Formula (I): or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.